Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Fürj u. 2. , Budapest, H-1124 Budapest,Hungary
Tel: +36 1 381 0765
Web: http://www.hyd.hu/
HYD LLC. for Cancer Research and Drug Development was established for the research, development and worldwide marketing of pharmaceutical and consumer products based on the proprietary procedure, deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploration of new indication fields for the application of deuterium-depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium-depleted water (DDW) was that tumor cells proved to be extremely sensitive to the withdrawal of deuterium (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and according to the latest results it can also influence other physiological processes like glucose metabolism.
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD’s approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.
HYD LLC. is marketing and distributing several products with decreased deuterium content in food and medicinal product categories. For human consumption Preventa® deuterium-depleted carbonated drinking water brand is available with different D-contents. Considering the D concentration of natural waters (140-150 ppm at our latitude), Preventa® products’ deuterium concentration varies between 125 and 45 ppm as it is indicated on the label. The products are mainly targeted on tumorous patients under conventional treatments or in remission and health-conscious consumers mostly in the age group over 40. It is made of deuterium-depleted water, natural mineral water and carbon dioxide. Preventa® is a registered trademark of HYD LLC.
VETERA-DDW-25® is medicinal preparation for veterinary use for the adjuvant therapy of neoplastic diseases of household pets. This first deuterium-depleted drug was registered in 1999. The active agent is deuterium-depleted water (DDW; 25 ppm D). Vetera-DDW-25® is mostly applied to dogs and cats suffering from cancer.
Several editions of the book „Defeating cancer!” written by Gábor Somlyai PhD are available in different languages and can be ordered from the Hungarian and foreign publishers.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here